474708-98-0

Basic information

• Product Name: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE
• Synonyms: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE;IMidazo[1,2-a]pyridine-3-carbonitrile, 6-broMo-;6-bromoimidazo[1,2-a]pyrazine-3-carbonitrile
• CAS NO: 474708-98-0
• Molecular Formula: C₈H₄BrN₃
• Molecular Weight: 222.045
• Mol File: 474708-98-0.mol

Chemical Properties

• Appearance: /
• Density: 1.71±0.1 g/cm3(Predicted)
• PKA: 0.86±0.50(Predicted)
• CAS DataBase Reference: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE(474708-98-0)
• EPA Substance Registry System: 6-BROMO-IMIDAZO[1,2-A]PYRIDINE-3-CARBONITRILE(474708-98-0)

Safety Data

• Hazardous Substances Data: 474708-98-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-imidazo[1,2-a]pyridine-3-carbonitrile is used as a building block for the synthesis of various pharmaceuticals due to its unique structure and reactivity. It contributes to the development of new chemical compounds with diverse applications in the treatment of various diseases and conditions.
Used in Agrochemical Industry:
In the agrochemical industry, 6-Bromo-imidazo[1,2-a]pyridine-3-carbonitrile is utilized as a key intermediate in the synthesis of agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control and crop protection, contributing to increased agricultural productivity.
Used in Organic Chemistry Research:
6-Bromo-imidazo[1,2-a]pyridine-3-carbonitrile is used as a valuable tool in organic chemistry research. Its unique structure allows researchers to explore its potential reactivity and applications in the synthesis of new organic compounds, expanding the scope of chemical reactions and products.
Used in Medicinal Chemistry Research:
6-Bromo-imidazo[1,2-a]pyridine-3-carbonitrile is employed in medicinal chemistry research for its potential biological activities. Its unique structure and reactivity make it an interesting candidate for the development of new chemical compounds with therapeutic properties, contributing to the advancement of drug discovery and development.

Upstream product

• 138240-34-3 (E)-N’-(5-bromopyridin-2-yl)-N,N-dimethylformamidine 
• 590-17-0 cyanomethyl bromide 
• 138888-98-9 N’-(5-bromopyridin-2-yl)-N,N-dimethylformimidamide 
• 1072-97-5 5-bromo-2-pyridylamine 
• 106-96-7 propargyl bromide 
• 107-14-2 chloroacetonitrile 
• 944896-42-8 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid 
• 2044706-79-6 6-bromoimidazo[1,2-a]pyridine-3-carboxamide 

Downstream Products

• 1004550-16-6 6-vinylimidazo[1,2-a]pyridine-3-carbonitrile 
• 1276110-12-3 N-(5-(3-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-benzenesulfonamide 
• 1276110-04-3 N-(5-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1276110-08-7 N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1276110-30-5 2,4-difluoro-N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1276110-33-8 N-(5-(3-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1276110-36-1 3,5-difluoro-N-(5-(3-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo[1,2-a]-pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 944896-42-8 6-bromoimidazo[1,2-a]pyridine-3-carboxylic acid 
• 1989745-33-6 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-3-carbonitrile 

Relevant articles and documents

AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are an aromatic heterocyclic compound, an intermediate thereof, a preparation method therefor, and a pharmaceutical composition and use thereof. The aromatic heterocyclic compound of the present invention is a new ALK5 inhibitor, and is used for treating and/or preventing various ALK5-mediated diseases.

AROMATIC HETEROCYCLIC SUBSTITUTED OLEFIN COMPOUND, PREPARATION METHOD FOR SAME, PHARMACEUTICAL COMPOSITION OF SAME, AND APPLICATIONS THEREOF

Provided in the present application are an aromatic heterocyclic substituted olefin compound, a preparation method for same, a pharmaceutical composition of same, and applications thereof. The aromatic heterocyclic substituted olefin compound of the present invention is a novel ALK5 inhibitor and is for use in treating and/or preventing various ALK5-mediated diseases.

SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

This disclosure relates to low molecular weight substituted imidazoles that inhibit the TGF-b signaling pathway. More specifically, this disclosure relates to methods of using said imidazoles for the treatment of diseases related to the TGF-b signaling pathways including, but not limited to, atherosclerosis, Marfan syndrome, Loeys-Dietz syndrome, obesity, diabetes, multiple sclerosis, keratoconus, idiopathic pulmonary fibrosis, Alzheimer's Disease, chronic kidney disease, and scleroderma.

Prospective evaluation and success of a machine learning hit-to-lead drug development program against phosphatidylinositol 3-kinase α

As a result of the rapidly increasing cost of drug development, efficient methods for early identification of compounds with a high probability of clinical success are needed. Herein, we describe a cheminformatics protocol which dramatically increases quality candidate identification and should reduce the attrition rate of compounds entering the clinic, increasing the cost-effectiveness of drug development. Against the oncology target phosphatidylinositol 3-kinase α, all five compounds synthesized from the protocol were found to have low nanomolar activity. We therefore propose that our protocol can be used as a tool for reducing the synthetic burden required for hit-to-lead optimization.

Convenient two-step one-pot synthesis of 3-substituted imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines

Abstract: A convenient and novel two-step one-pot method for the synthesis of 3-substituted imidazo[1,2-a]pyridines and 3-substituted imidazo[1,2-b]pyridazines was developed through the reaction of heterocyclic amines and N,?N-dimethylformamide dimethyl a

PHOSPHOTIDYLINOSITOL 3-KINASE INHIBITORS

This disclosure relates to phosphoinositide 3-kinases (PI3Ks) inhibitors such as N-(5-(imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)sulfonamide derivatives and uses related thereto. In certain embodiments, the disclosure relates to methods of treating PI3K associated diseases or conditions comprising administering an effective amount of a compound disclosed herein to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, suffering from, or diagnosed with cancer or a hematological malignancy.

TGF-Beta Inhibitors

Disclosed are imidazole and thiazole compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein X, A, Z, R1 and R′ are as described herein. In certain embodiments, a compound disclosed herein inhibits TGF-β, and can be used to treat disease by blocking TGF-β signaling.

Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis

Phosphatidylinositol 3-kinase α (PI3Kα) is an important regulator of intracellular signaling pathways, controlling remarkably diverse arrays of physiological processes. Because the PI3K pathway is frequently up-regulated in human cancers, the inhibition of PI3Kα can be a promising approach to cancer therapy. In this study, we have designed and synthesized a new series of imidazo[1,2-a]pyridine derivatives as PI3Kα inhibitors through the fragment-growing strategy. By varying groups at the 3- and 6-positions of imidazo[1,2-a]pyridines, we studied the structure-activity relationships (SAR) profiles and identified a series of potent PI3Kα inhibitors. Representative derivatives showed good activity in cellular proliferation and apoptosis assays. Moreover, these inhibitors exhibited noteworthy antiangiogenic activity.

PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PB kinases using pyridosulfonamide derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of pyridosulfonamide derivatives.

THIOZOLIDINEDIONE DERIVATIVES AS P13 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PB kinases using thiozolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of thiozolidinedione derivatives.